Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
About Eli Lilly and Company
Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.
Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly
3369 articles about Eli Lilly and Company
-
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
11/14/2023
Eli Lilly and Company announced that the U.S. NRC has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s radioactive materials license, which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
-
The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached.
-
At its highest dose level of 608 mg, lepodisiran reduced lipoprotein(a) levels by a median of 94% after 48 weeks.
-
The FDA’s approval of Eli Lilly’s obesity drug Zepbound intensifies an already heated battle with Novo Nordisk’s Wegovy in the lucrative weight-loss drug market, as other drugmakers hope to get a piece of the action.
-
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
11/8/2023
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
-
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
11/8/2023
Eli Lilly and Company announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of POINT Biopharma Global Inc., for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.
-
Lilly’s Zepbound (tirzepatide) injection is the first and only approved treatment that activates two incretin hormone receptors, GIP and GLP-1, to treat obesity and excess weight.
-
Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro drove blockbuster sales in the third quarter and the sky’s the limit for the duopoly. The only limiting factor is that the frenzied demand for their respective drugs is outpacing supply.
-
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
11/2/2023
Lilly defines New Products as select products launched since 2022, which currently consist of Jaypirca, Mounjaro and Omvoh.
-
Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting
11/2/2023
Eli Lilly and Company announced that data from studies of pirtobrutinib, a non-covalent Bruton's tyrosine kinase inhibitor, will be presented at the 65th American Society of Hematology Annual Meeting and Exposition taking place December 9-12 in San Diego.
-
Sales of type 2 diabetes treatment Mounjaro brought in $1.4 billion in the third quarter. However, the company cut its full-year profit guidance due to charges mainly related to recent acquisitions.
-
Lilly Declares Fourth-Quarter 2023 Dividend
11/1/2023
The board of directors of Eli Lilly and Company has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock.
-
Redwire Announces First Spaceflight Mission for New Cutting-Edge Pharmaceutical Drug Development Lab, Partnering with Eli Lilly and Company to Expand Space Research to Study Heart Disease and Diabetes
10/30/2023
Redwire Corporation announced today the first spaceflight mission for its cutting-edge in-space pharmaceutical manufacturing platform, PIL-BOX, designed to offer pharmaceutical companies and researchers novel and flexible services to grow small-batch crystals of protein-based pharmaceuticals and other key pharmaceutically relevant molecules for research.
-
Following an FDA rejection and a previous discontinuation in psoriasis, Eli Lilly’s anti-IL-23 antibody has finally won an approval in ulcerative colitis, joining a crowded inflammatory bowel disease market.
-
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
10/26/2023
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
-
Lilly to Participate in UBS Biopharma Conference 2023
10/26/2023
Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.
-
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive NSCLC and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
10/21/2023
Eli Lilly and Company announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® versus platinum-based chemotherapy.
-
Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years
10/20/2023
Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company.
-
Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement
10/20/2023
Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023.
-
Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
10/20/2023
Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years of adjuvant Verzenio® (abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence.